Leadership decisions that shaped the destiny of Genzyme: Lessons from 30 years of entrepreneurial leadership: critical decisions for growth

Marianne van der Steen, Paula Englis-Danskin

Research output: Contribution to journalArticleAcademic

21 Downloads (Pure)

Abstract

This article is based on an interview of Marianne van der Steen with Henri Termeer‐the long time CEO of Genzyme. Within Europe, Genzyme’s state-of-the-art cell culture production facility for therapeutic proteins is located in Geel, Belgium, and is among the largest bio‐manufacturing sites in Europe. This month, the company announced that it will build an additional manufacturing plant in Geel. The topic of the interview was growth decisions from biotech start-up to a fully integrated biopharma company. Henri Termeer, CEO, President and Chairman of Genzyme, looked back at 30 years of experience building a biopharma company. Henri talked about leadership decisions at the critical junctures of building a biopharma company. What are the lessons for European biotech entrepreneurs? How to breed European Gazelles?
Original languageEnglish
Pages (from-to)-
Number of pages5
JournalMIRA newsletter
Publication statusPublished - 2011

Keywords

  • IR-94067
  • METIS-309018

Fingerprint Dive into the research topics of 'Leadership decisions that shaped the destiny of Genzyme: Lessons from 30 years of entrepreneurial leadership: critical decisions for growth'. Together they form a unique fingerprint.

Cite this